Developer docs
API playgroundTry for free, no card

Search company profiles

Prothena

Full company profile

uuid0000rcd

Namestring
Prothena
Legal namestring
Prothena Corporation plc
Websiteurl
prothena.com
Company typeenum
Public
Founded yearint
2012
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
monoclonal antibody therapeutics, neurodegenerative disease therapies, protein misfolding research, rare amyloid disease treatments, clinical-stage biotechnology
Industry3 codes
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Clinical-stage Biopharmaceuticals (Neuroscience)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Milestone Payments from Partners
TypeLicensing Royalties
Description

Prothena receives milestone payments from strategic partners upon achievement of clinical, regulatory, and commercial development milestones. Currently earning milestones from Novo Nordisk ($1.2B total potential) and Bristol Myers Squibb partnerships.

pharmiweb.com
2Future Product Revenue
TypeLicensing Royalties
Description

Post-approval, the company will receive royalties and/or milestone payments from partnered programs commercialized by Roche (prasinezumab), Novo Nordisk (coramitug), and Bristol Myers Squibb (BMS-986446). Prothena retains certain co-development rights and potential sales-based payments.

businesswire.com
3Clinical Milestones
TypeLicensing Royalties
Description

Near-term revenue opportunity from up to $105 million in aggregate clinical milestone payments from strategic partners Novo Nordisk and Bristol Myers Squibb expected in 2026.

businesswire.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Prothena is a clinical-stage biotechnology company that discovers and develops monoclonal antibody therapeutics targeting misfolded proteins (alpha-synuclein, tau, transthyretin) for neurodegenerative and rare peripheral amyloid diseases including Parkinson's disease, Alzheimer's disease, ATTR amyloidosis, and ALS. The company develops its drug candidates through internal discovery and out-licenses them to major pharmaceutical partners (Roche, Novo Nordisk, Bristol Myers Squibb) for clinical development and global commercialization, retaining co-development involvement and milestone/royalty rights.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Prasinezumab showed slowing of motor progression in rapidly progressing early-stage Parkinson's disease patients in PADOVA Phase 2b trial (Lancet, May 2026)
+4 more records
Product overview1 text field

Prothena is a clinical-stage biotechnology company with a diversified pipeline of novel investigational therapies targeting neurodegenerative and rare peripheral amyloid diseases. The company's portfolio includes six key programs: Prasinezumab (Parkinson's disease, partnered with Roche, Phase 3), Coramitug/PRX004 (ATTR amyloidosis, partnered with Novo Nordisk, Phase 3), BMS-986446/PRX005 (Alzheimer's disease, partnered with Bristol Myers Squibb, Phase 2), PRX019 (neurodegenerative diseases, Phase 1), and two preclinical programs (TDP-43 CYTOPE for ALS and PRX012-TfR for Alzheimer's disease). The company leverages deep expertise in protein dysregulation and antibody targeting to develop disease-modifying therapeutics.

Product and service6 records
1Prasinezumab
CategoryMonoclonal antibody therapeutic — Parkinson's disease
2Coramitug (PRX004)
CategoryMonoclonal antibody therapeutic — ATTR amyloidosis
3BMS-986446 (PRX005)
CategoryMonoclonal antibody therapeutic — Alzheimer's disease
4PRX019
CategoryMonoclonal antibody therapeutic — Neurodegenerative diseases
5TDP-43 CYTOPE Program
CategoryMonoclonal antibody therapeutic — ALS / TDP-43 proteinopathies
6PRX012-TfR
CategoryMonoclonal antibody therapeutic — Alzheimer's disease (blood-brain barrier shuttle)
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Academic/Research Institutions
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

Collaboration with academic researchers and institutions for scientific presentations and research, including presentation of TDP-43 CYTOPE program data at Neuroscience 2025 conference.

biospace.com
2Bristol Myers Squibb
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Global Neuroscience Research and Development Collaboration for BMS-986446 (PRX005) targeting tau for Alzheimer's disease. Bristol Myers Squibb responsible for all communication, development, manufacturing, and commercialization. Phase 2 TargetTau-1 trial fully enrolled. PRX019 also licensed to BMS in 2024 for neurodegenerative diseases.

prothena.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-01
Description

Acquisition agreement where Novo Nordisk acquired worldwide rights to Prothena's ATTR amyloidosis program including coramitug (PRX004). Prothena eligible to receive up to $1.2 billion in milestone payments, with $150 million earned to date. Novo Nordisk leads Phase 3 CLEOPATTRA trial and future global commercialization. FDA Fast Track Designation obtained for coramitug in ATTR-CM.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2012-12-01
Description

Worldwide collaboration between Prothena and Roche for prasinezumab (anti-α-synuclein antibody) for Parkinson's disease. Roche leads global clinical development (Phase 3 PARAISO trial ongoing) and commercialization. Prothena co-developed the antibody and receives milestone payments and royalties. This is a flagship partnership for Prothena's lead Parkinson's disease program.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing oligonucleotide therapeutics for neurological diseases including Huntington's, ALS, and Parkinson's. Comparable size, clinical stage, and focus on hard-to-treat neurological indications.

TypeBroad incumbent
Description

Large-cap neurology biotech with Alzheimer's franchise (Leqembi, partnered with Eisai) and broad neurodegenerative pipeline. Comparable to Prothena in disease focus (Alzheimer's, Parkinson's, ALS) but vastly larger and commercially established.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics for neurodegenerative diseases using antibody and small molecule approaches targeting lysosomal function and protein aggregation. Closely comparable in size, clinical stage, neurology focus, and partnered model (e.g., Sanofi collaboration).

TypeDirect peer
Description

Leader in RNA interference therapeutics with Onpattro and Amvuttra approved for ATTR amyloidosis, directly competing with Prothena's coramitug in the same ATTR indication. Comparable in targeting misfolded proteins but with siRNA rather than antibody modality.

TypeDirect peer
Description

Commercial-stage biotech with Attruby (acoramidis) approved for ATTR-CM, directly competing with coramitug. Comparable in indication focus and partnership-heavy development model with multiple partnered programs.

6Eisai
TypeBroad incumbent
Description

Large Japanese pharma with Leqembi for Alzheimer's, partnered with Biogen. Competes with Prothena's BMS-986446 in tau-targeting for AD. Notably, Prothena's CDO Chad Swanson led lecanemab's clinical development at Eisai.

TypeDirect peer
Description

Antisense oligonucleotide platform company with neurology pipeline including TTR amyloidosis (eplontersen, partnered with AstraZeneca) and ALS programs. Comparable in targeting neurological diseases via novel modalities and heavy partnership model.

8Cassava Sciences
TypeEmerging player
Description

Clinical-stage biotech focused on Alzheimer's disease with simufilam in Phase 3. Comparable in clinical-stage neuroscience focus but smaller and single-asset versus Prothena's diversified pipeline.

TypeDirect peer
Description

Clinical-stage gene therapy company focused on neurological diseases including Parkinson's (VY-AADC), ALS, and Huntington's. Comparable in clinical stage, neuroscience focus, and partnership-driven model (e.g., Pfizer, Neurocrine partnerships).

TypeEmerging player
Description

Clinical-stage biotech developing therapeutics for Alzheimer's, Parkinson's, and Rett syndrome. Comparable in clinical-stage neurology focus and protein-misfolding disease targets but uses small molecules rather than antibodies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prothena

Clinical-stage Biopharmaceuticals (Neuroscience)prothena.com

Prothena firmographics

Firmographics
Name
Prothena
Legal name
Prothena Corporation plc
Website
https://prothena.com
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Prothena industry classification

Industry
Product category
Clinical-stage Biopharmaceuticals (Neuroscience)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Monoclonal antibody therapeutics
  • Neurodegenerative disease therapies
  • Protein misfolding research
  • Rare amyloid disease treatments
  • Clinical-stage biotechnology

Where Prothena is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Offices2 records

Markets served

Prothena business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Milestone Payments from Partners: Prothena receives milestone payments from strategic partners upon achievement of clinical, regulatory, and commercial development milestones. Currently earning milestones from Novo Nordisk ($1.2B total potential) and Bristol Myers Squibb partnerships.
  2. Future Product Revenue: Post-approval, the company will receive royalties and/or milestone payments from partnered programs commercialized by Roche (prasinezumab), Novo Nordisk (coramitug), and Bristol Myers Squibb (BMS-986446). Prothena retains certain co-development rights and potential sales-based payments.
  3. Clinical Milestones: Near-term revenue opportunity from up to $105 million in aggregate clinical milestone payments from strategic partners Novo Nordisk and Bristol Myers Squibb expected in 2026.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Prothena product offering

Product offering

Core offering

Prothena is a clinical-stage biotechnology company that discovers and develops monoclonal antibody therapeutics targeting misfolded proteins (alpha-synuclein, tau, transthyretin) for neurodegenerative and rare peripheral amyloid diseases including Parkinson's disease, Alzheimer's disease, ATTR amyloidosis, and ALS. The company develops its drug candidates through internal discovery and out-licenses them to major pharmaceutical partners (Roche, Novo Nordisk, Bristol Myers Squibb) for clinical development and global commercialization, retaining co-development involvement and milestone/royalty rights.

Product overview

Prothena is a clinical-stage biotechnology company with a diversified pipeline of novel investigational therapies targeting neurodegenerative and rare peripheral amyloid diseases. The company's portfolio includes six key programs: Prasinezumab (Parkinson's disease, partnered with Roche, Phase 3), Coramitug/PRX004 (ATTR amyloidosis, partnered with Novo Nordisk, Phase 3), BMS-986446/PRX005 (Alzheimer's disease, partnered with Bristol Myers Squibb, Phase 2), PRX019 (neurodegenerative diseases, Phase 1), and two preclinical programs (TDP-43 CYTOPE for ALS and PRX012-TfR for Alzheimer's disease). The company leverages deep expertise in protein dysregulation and antibody targeting to develop disease-modifying therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

  • Prasinezumab
  • Coramitug (PRX004)
  • BMS-986446 (PRX005)
  • PRX019
  • TDP-43 CYTOPE Program
  • PRX012-TfR

Quantifiable outcome

  • Prasinezumab showed slowing of motor progression in rapidly progressing early-stage Parkinson's disease patients in PADOVA Phase 2b trial (Lancet, May 2026)
  • +4 more outcomes

Companies that use Prothena

Customer profile

Segments4 records

Ideal customer profiles1 record

Prothena technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Prothena partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • Academic/Research InstitutionsminorStrategic or Co-development Partner · 1 November 2025Collaboration with academic researchers and institutions for scientific presentations and research, including presentation of TDP-43 CYTOPE program data at Neuroscience 2025 conference.
  • Bristol Myers SquibbcoreStrategic or Co-development Partner · 1 January 2022Global Neuroscience Research and Development Collaboration for BMS-986446 (PRX005) targeting tau for Alzheimer's disease. Bristol Myers Squibb responsible for all communication, development, manufacturing, and commercialization. Phase 2 TargetTau-1 trial fully enrolled. PRX019 also licensed to BMS in 2024 for neurodegenerative diseases.
  • Novo NordiskcoreStrategic or Co-development Partner · 1 July 2021Acquisition agreement where Novo Nordisk acquired worldwide rights to Prothena's ATTR amyloidosis program including coramitug (PRX004). Prothena eligible to receive up to $1.2 billion in milestone payments, with $150 million earned to date. Novo Nordisk leads Phase 3 CLEOPATTRA trial and future global commercialization. FDA Fast Track Designation obtained for coramitug in ATTR-CM.
  • RochecoreStrategic or Co-development Partner · 1 December 2012Worldwide collaboration between Prothena and Roche for prasinezumab (anti-α-synuclein antibody) for Parkinson's disease. Roche leads global clinical development (Phase 3 PARAISO trial ongoing) and commercialization. Prothena co-developed the antibody and receives milestone payments and royalties. This is a flagship partnership for Prothena's lead Parkinson's disease program.

Scale indicators12 records

Recent moves9 records

Expansion highlights5 records

Prothena competitors and assessment

Company assessment

Direct peers

  • Wave Life Sciences: Clinical-stage biotech developing oligonucleotide therapeutics for neurological diseases including Huntington's, ALS, and Parkinson's. Comparable size, clinical stage, and focus on hard-to-treat neurological indications.
  • Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegenerative diseases using antibody and small molecule approaches targeting lysosomal function and protein aggregation. Closely comparable in size, clinical stage, neurology focus, and partnered model (e.g., Sanofi collaboration).
  • Alnylam Pharmaceuticals: Leader in RNA interference therapeutics with Onpattro and Amvuttra approved for ATTR amyloidosis, directly competing with Prothena's coramitug in the same ATTR indication. Comparable in targeting misfolded proteins but with siRNA rather than antibody modality.
  • BridgeBio Pharma: Commercial-stage biotech with Attruby (acoramidis) approved for ATTR-CM, directly competing with coramitug. Comparable in indication focus and partnership-heavy development model with multiple partnered programs.
  • Ionis Pharmaceuticals: Antisense oligonucleotide platform company with neurology pipeline including TTR amyloidosis (eplontersen, partnered with AstraZeneca) and ALS programs. Comparable in targeting neurological diseases via novel modalities and heavy partnership model.
  • Voyager Therapeutics: Clinical-stage gene therapy company focused on neurological diseases including Parkinson's (VY-AADC), ALS, and Huntington's. Comparable in clinical stage, neuroscience focus, and partnership-driven model (e.g., Pfizer, Neurocrine partnerships).

Broad incumbents

  • Biogen: Large-cap neurology biotech with Alzheimer's franchise (Leqembi, partnered with Eisai) and broad neurodegenerative pipeline. Comparable to Prothena in disease focus (Alzheimer's, Parkinson's, ALS) but vastly larger and commercially established.
  • Eisai: Large Japanese pharma with Leqembi for Alzheimer's, partnered with Biogen. Competes with Prothena's BMS-986446 in tau-targeting for AD. Notably, Prothena's CDO Chad Swanson led lecanemab's clinical development at Eisai.

Emerging players

  • Cassava Sciences: Clinical-stage biotech focused on Alzheimer's disease with simufilam in Phase 3. Comparable in clinical-stage neuroscience focus but smaller and single-asset versus Prothena's diversified pipeline.
  • Anavex Life Sciences: Clinical-stage biotech developing therapeutics for Alzheimer's, Parkinson's, and Rett syndrome. Comparable in clinical-stage neurology focus and protein-misfolding disease targets but uses small molecules rather than antibodies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Prothena social profiles

Digital presence

Prothena financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prothena leadership team

Management profile

Number of profiles

Profiles14 records

Prothena funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prothena M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prothena

What does Prothena do?

Prothena is a clinical-stage biotechnology company that discovers and develops monoclonal antibody therapeutics targeting misfolded proteins (alpha-synuclein, tau, transthyretin) for neurodegenerative and rare peripheral amyloid diseases including Parkinson's disease, Alzheimer's disease, ATTR amyloidosis, and ALS. The company develops its drug candidates through internal discovery and out-licenses them to major pharmaceutical partners (Roche, Novo Nordisk, Bristol Myers Squibb) for clinical development and global commercialization, retaining co-development involvement and milestone/royalty rights.

Is Prothena a public or private company?

Prothena is a public company. It is classified as public and is currently operating.

When was Prothena founded?

Prothena was founded in 2012. It employs 51 to 100 people.

Where is Prothena based?

Prothena is headquartered in Dublin, Ireland, in the Europe region.

How does Prothena make money?

Three revenue lines are on record. Milestone Payments from Partners are the primary driver. The others are future Product Revenue and clinical Milestones.

Who are Prothena's main competitors?

Direct peers on record are Wave Life Sciences, Denali Therapeutics, Alnylam Pharmaceuticals, BridgeBio Pharma, Ionis Pharmaceuticals and Voyager Therapeutics. Broad incumbents are Biogen and Eisai. Emerging players are Cassava Sciences and Anavex Life Sciences.

Does Prothena have an API?

No public API is recorded for Prothena.

What industry is Prothena in?

Prothena's product category is Clinical-stage Biopharmaceuticals (Neuroscience). Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldProthena Corporation plc (NASDAQ:PRTA) Stock Has Average Target Price of $20.00Prothena Corporation shares have a consensus "Moderate Buy" rating with an average target price of $20.00. Major shareholder William P. Scully bought 50,000 shares at $8.07, and the company reported a Q3 loss of $0.32 per share, missing the consensus estimate of $0.23.American Banking and Market NewsProthena Corporation plc (NASDAQ:PRTA) Stock Now Rated “Moderate Buy” by Sell-Side AnalystsProthena Corporation shares received a consensus "Moderate Buy" rating from seven analysts, with an average price target of $20.00. Major shareholder William P. Scully bought 50,000 shares at $8.07, and the company reported a Q3 loss of $0.32 per share, missing estimates. Analysts forecast 0.08 EPS for the current fiscal year.YahooProthena: Q3 Earnings SnapshotProthena Corp. reported a third-quarter loss of $16.5 million, or 32 cents per share, on Thursday. The result beat Wall Street estimates, which expected a loss of 38 cents per share. Revenue for the period was $620,000.Business Wire BlogProthena to Report Third Quarter 2026 Financial Results on November 5Prothena Corporation will report its third quarter and first nine months of 2026 financial results on November 5, 2026, after U.S. market close, without a conference call. The company's pipeline includes programs for Parkinson's disease, ATTR amyloidosis, Alzheimer's, and ALS, using its CYTOPE® technology.BioSpaceBMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beatBristol Myers Squibb shelved two biotech-partnered pipeline candidates after reviewing early data, including a neurodegeneration drug and a blood cancer asset. The company raised its full-year revenue outlook by 1% to $49.75–$50.25 billion after Q3 revenue beat of $13.1 billion. It also confirmed ongoing development of its Alzheimer's drug moponetug.MarketBeatProthena (PRTA) Projected to Release Earnings on ThursdayProthena is expected to report Q3 2026 earnings on Thursday, November 5th, with analysts projecting a loss of $0.2271 per share and revenue of $9.58 million. The company's stock opened at $9.10, and analysts have an average rating of Moderate Buy with a price target of $20.00.FierceBiotechBMS walks away from $80M neurodegeneration bet after phase 1Bristol Myers Squibb scrapped a phase 1 program it licensed from Prothena for $80 million, after reviewing phase 1 data. The decision follows Prothena's completion of a phase 1 study in healthy adults, and BMS did not disclose the findings. The broader neuroscience partnership continues, including an Alzheimer's candidate.TradingViewProthena 10% Owner Purchased Shares Worth Over $1.2MWilliam P. Scully, a 10% owner of Prothena, purchased 150,000 ordinary shares in two transactions at weighted average prices of $8.1852 and $8.0705 per share, totaling $1,222,045. After the purchases, he directly owned 1,187,000 shares and indirectly owned 716,000 shares.TradingViewProthena 10% Owner Purchased Shares Worth Over $920KWilliam P. Scully, a 10% owner of Prothena, purchased 110,000 ordinary shares on October 13-14, 2026, at weighted average prices of $8.3548 and $8.4569, totaling $920,048. After the transactions, he directly owns 1,037,000 shares and indirectly owns 716,000 shares.Defense WorldProthena Corporation plc (NASDAQ:PRTA) Stock Has Average Price Target of $24.57Prothena Corporation shares received a consensus 'Moderate Buy' rating with an average price target of $24.57. The stock opened at $8.43, and the company reported a quarterly loss of $0.32 per share, beating estimates of $0.39. Insiders sold shares, while institutional ownership remains high.